ArticleDiabetes care2022

Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.

Dhruv Mahtta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.